DUBLIN--(BUSINESS WIRE)--The "RGN-259 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. RGN-259, a TB4-based sterile and preservative-free eye ...
BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has enrolled the first subject in its Phase IB clinical trial in which RGN-352 ...
RegeneRx Seeking Strategic Partnership to Address CF in U.S. and Europe BETHESDA, Md., Oct. 1, 2008--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results